Core Insights - Hims & Hers Health has officially launched its testosterone replacement therapy (TRT) options, which has positively impacted its stock price, reflecting strong market anticipation for this product line [1][2][3]. Product Offerings - The company will offer four TRT options in partnership with Marius Pharmaceuticals, including a pill called Kyzatrex and an injectable testosterone, with a compounded version of enclomiphene available immediately [4][5]. - Pricing for the TRT options is expected to range from $99 to $199 per month, depending on the plan duration [2][5]. Market Performance - Following the announcement, Hims stock rose nearly 7% to $51.07, surpassing its 50-day moving average, indicating positive market sentiment [3]. - Analyst Michael Cherny noted that while the TRT launch will support growth, the stock's performance is more closely tied to the durability and upside potential of the company's weight management growth [3]. Future Outlook - The introduction of Kyzatrex is planned for 2026, and the company aims to enhance its treatment offerings with a focus on restoring natural testosterone production [4].

Hims & Hers Health Inc. HIMS launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.An estimated 20 million men in the U.S. struggle with low testosterone.Bloomberg earlier reported the update. The telehealth company's latest move comes as its weight-loss drug sales have slowed, impacting its stock performance in recent months. The new offerings aim to bolster its core sexual health services and tap into an underserved market ...